At the start of the year, there had been no new therapies for rare cholestatic liver disease primary biliary cholangitis (PBC) in the US for almost a decade. With the FDA approval of Gilead's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback